Intermede Investment Partners Ltd grew its position in shares of Danaher Co. (NYSE:DHR) by 4.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 465,665 shares of the conglomerate’s stock after buying an additional 21,809 shares during the period. Danaher accounts for approximately 3.7% of Intermede Investment Partners Ltd’s holdings, making the stock its 16th largest holding. Intermede Investment Partners Ltd’s holdings in Danaher were worth $43,223,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GQG Partners LLC bought a new stake in shares of Danaher in the second quarter worth $101,000. Zions Bancorporation increased its stake in shares of Danaher by 118.3% in the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after buying an additional 667 shares during the last quarter. Patten Group Inc. increased its stake in shares of Danaher by 262.3% in the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after buying an additional 3,497 shares during the last quarter. Monetary Management Group Inc. increased its stake in shares of Danaher by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after buying an additional 150 shares during the last quarter. Finally, Acrospire Investment Management LLC increased its stake in shares of Danaher by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after buying an additional 1,100 shares during the last quarter. Institutional investors own 76.11% of the company’s stock.

In other news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the transaction, the chief executive officer now directly owns 271,737 shares of the company’s stock, valued at approximately $25,173,715.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 273,810 shares of company stock valued at $25,218,813. 12.20% of the stock is currently owned by corporate insiders.

A number of brokerages recently issued reports on DHR. Goldman Sachs Group restated a “neutral” rating and issued a $83.00 price target on shares of Danaher in a research note on Tuesday, September 26th. Evercore ISI began coverage on shares of Danaher in a research note on Wednesday, January 3rd. They issued an “outperform” rating for the company. Robert W. Baird restated a “buy” rating on shares of Danaher in a research note on Friday, January 12th. Royal Bank of Canada restated a “hold” rating and issued a $96.00 price target on shares of Danaher in a research note on Thursday, January 4th. Finally, Cowen restated a “buy” rating and issued a $90.00 price target on shares of Danaher in a research note on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $94.91.

Danaher Co. (NYSE:DHR) traded up $0.82 during trading on Friday, reaching $100.56. 2,872,583 shares of the company’s stock were exchanged, compared to its average volume of 2,432,008. The firm has a market capitalization of $69,950.00, a P/E ratio of 29.93, a PEG ratio of 2.16 and a beta of 1.03. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher Co. has a 1 year low of $78.97 and a 1 year high of $100.88.

Danaher (NYSE:DHR) last released its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05. The firm had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.87 earnings per share. research analysts predict that Danaher Co. will post 3.99 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s dividend payout ratio is presently 16.67%.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/intermede-investment-partners-ltd-has-43-22-million-stake-in-danaher-co-dhr/1814363.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.